Table 3.

Association between median week 14 vedolizumab trough level (VTL) and clinical and endoscopic outcomes for all patients.^a

	Median W14 VTL, µg/ml	IQR		Median W14 VTL, µg/ml	IQR	p
W14 remitters	22.3	18.3–31.4	W14 non-remitters	15.6	9–20.9	0.0001
W14 remitters plus normal CRP	20.6	18.6–34.7	W14 non-remitters and/or without normal CRP	17.2	10.2–23.2	0.006
W22 remitters	22.4	18.6–32.2	W22 non-remitters	14.2	9–20.9	<0.0001
W22 remitters plus normal CRP	20.8	19–30.5	W22 non-remitters and/or without normal CRP	16.2	9.5–27.6	0.004
W54 remitters	20.9	16.9–31.4	W54 non-remitters	15.9	8.5–19.5	0.008
W54 remitters plus normal CRP	20	17.8–26.9	W54 non-remitters and/or without normal CRP	14.5	8–20.9	0.03
MH at W54	20.4	16.9–25.9	No MH at W54	11.9	7.3–17.4	0.0008

CRP: C-reactive protein; IQR: interquartile range; MH: mucosal healing.

^aMH data are referred to patients having both baseline and follow-up endoscopy.